15 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $87M | -$57M | 57.7% | -56.1% | $5M | $36M | $9M |
| 2025 | — | -$12M | — | — | — | $34M | $7M |
| 2024 | $94M | -$12M | 58.2% | -6.6% | -$1M | $37M | $4M |
| 2023 | $112M | -$3M | 58.9% | 1.7% | $12M | $37M | $4M |
| 2022 | $113M | -$10M | 53.7% | -6.1% | -$438000 | $47M | $5M |
| 2021 | $119M | -$288000 | 56.9% | 1.7% | $67000 | $48M | $8M |
| 2020 | $102M | -$8M | 56.8% | 0.2% | $8M | $48M | $8M |
| 2019 | $116M | -$5M | 55.4% | 0.3% | $7M | $54M | $8M |
| 2018 | $121M | -$3M | 52.3% | 0.8% | $2M | $61M | $8M |
| 2017 | — | -$865000 | — | — | $167000 | $12M | $6M |
| 2016 | — | -$4M | — | — | — | $14M | $6M |
| 2015 | — | -$19M | — | — | — | $19M | $7M |
| 2014 | — | $2M | — | — | — | $21M | $14M |
| 2013 | — | -$2M | — | — | — | $25M | $26M |
| 2012 | — | $2M | — | — | — | $13M | $21M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $21M | -$3M | 59.0% | -5.7% | -$1M | $36M | $7M |
| Dec '25 | $24M | -$3M | 59.7% | 7.2% | -$545000 | $36M | $9M |
| Sep '25 | $21M | -$1M | 58.4% | 1.0% | $877000 | $34M | $7M |
| Jun '25 | $20M | -$2M | 56.4% | -4.0% | $3M | $35M | $7M |
| Mar '25 | $22M | -$50M | 56.0% | -228.1% | $2M | $36M | $6M |
| Dec '24 | $25M | $18000 | 57.1% | 0.0% | $1M | $37M | $4M |
| Sep '24 | $22M | -$5M | 58.1% | -8.5% | -$2M | $35M | $5M |
| Jun '24 | $23M | -$3M | 57.2% | -9.0% | -$2M | $36M | $4M |
| Mar '24 | $25M | -$5M | 60.3% | -9.3% | $758000 | $36M | $4M |
| Dec '23 | $28M | -$2M | 58.0% | 1.0% | $3M | $37M | $4M |
| Sep '23 | $25M | -$1M | 58.1% | -3.7% | $4M | $39M | $5M |
| Jun '23 | $29M | -$980000 | 58.0% | 2.8% | $3M | $41M | $4M |
| Mar '23 | $30M | $622000 | 61.2% | 5.8% | $2M | $44M | $4M |
| Dec '22 | $28M | -$2M | 55.7% | -1.6% | $2M | $47M | $5M |
| Sep '22 | $27M | -$3M | 45.2% | -14.0% | $207000 | $49M | $5M |
| Jun '22 | $29M | $2M | 57.0% | 13.7% | -$632000 | $48M | $4M |
| Mar '22 | $29M | -$7M | 56.2% | -23.3% | -$2M | $49M | $5M |
| Dec '21 | $33M | $961000 | 59.2% | 5.1% | -$241000 | $48M | $8M |
| Sep '21 | $30M | -$170000 | 55.0% | 1.8% | -$1M | $45M | $6M |
| Jun '21 | $29M | -$410000 | 56.0% | 0.2% | $562000 | $43M | $6M |
How the market has priced HBIO against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, HARVARD BIOSCIENCE INC's revenue has declined 3.3% per year. These are computed facts, not advice.
As of FY2025, HARVARD BIOSCIENCE INC reported $36M of total debt against $9M of cash.
In FY2025, gross margin was 57.7%, operating margin -56.1%, and net margin -65.5%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.